Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 06, 2026
Why Is TripAdvisor (TRIP) Stock Down -26.09% Today?

Why Is TripAdvisor (TRIP) Stock Down -26.09% Today?

Key Takeaways

  • TripAdvisor shares plummeted 26.09% to $10.34 on Thursday, erasing months of gains after the company reported a significant second-quarter revenue and earnings miss.
  • Q2 revenue of $441.9 million fell 12.6% short of the $505.46 million consensus estimate, while adjusted EPS of $0.35 missed the $0.37 analyst expectation.
  • Weak forward guidance rattled investors, with management projecting Q3 continuing operations revenue declines of 7% to 10% and signaling persistent headwinds in its legacy Hotels segment.
  • SEO pressure, weakening U.S.-to-Europe travel demand, and declining average booking values were cited as key factors behind the disappointing results.
  • The selloff overshadowed the company's strategic progress, including the pending $700 million sale of TheFork to American Express and an accelerating pivot toward the Experiences segment led by Viator.
  • Traders are now watching for any stabilization around current levels and whether the TheFork deal proceeds can support share repurchases or debt reduction that might restore confidence.

Opening Summary

TRIP, the parent company of TripAdvisor, Inc. — one of the world's largest online travel guidance and booking platforms — saw its stock crater on Thursday, August 6, 2026, after second-quarter earnings dramatically undershot Wall Street expectations. Shares closed the previous session at $13.99 and plunged to $10.34 during Thursday's trading, a decline of 26.09%. The selloff was triggered by a combination of a steep revenue shortfall, an earnings-per-share miss, and cautious forward guidance that pointed to continued near-term deterioration in the company's legacy hotel advertising business.

Earnings Miss Sparks Massive Selloff

The primary catalyst behind Thursday's collapse was TripAdvisor's Q2 2026 earnings report, released before the market opened. The company posted adjusted earnings per share of $0.35, missing the $0.37 consensus by approximately 5.4%. More alarming to investors was the top-line performance: revenue from continuing operations came in at $441.9 million, a full 12.6% below the $505.46 million analyst estimate and down 7.2% from $476 million in the same quarter last year.

GAAP net income fell to $22.4 million, or $0.19 per share, compared to $36 million, or $0.28 per share, in the prior-year period. The core Hotels & Other segment bore the brunt of the weakness, with revenue declining 21% year-over-year to $163 million, while the Experiences segment — now the company's strategic focal point — generated $279 million, roughly flat compared to the prior year's $271 million.

Weak Guidance Deepens Investor Concern

Compounding the earnings disappointment, management issued a cautious outlook for the third quarter that left little room for optimism. The company guided for continuing operations revenue to decline 7% to 10% sequentially, with Hotels & Other revenue projected to fall by 20% to 23%. Experiences booked growth is expected at 5% to 7%, but revenue from the segment could range from a 2% decline to a 1% gain. Adjusted EBITDA margins were forecast at 17% to 20%, down from the 20% margin posted in Q2 2025.

CFO Mike Noonan acknowledged "weakening overall demand in the U.S.-to-Europe travel corridor, our largest corridor" and "pressure on average booking values, driven primarily from a higher mix of lower-priced experiences." Management also noted that SEO-related headwinds shaved approximately 5 percentage points off growth at the TripAdvisor point of sale, and that weather-related disruptions and cancellations weighed on results. While executives characterized these pressures as "transitory rather than structural," the market's reaction suggested deep skepticism.

Strategic Transformation Overshadowed

Ironically, the selloff came on the same day the company presented an investor deck outlining what management described as the largest long-term growth opportunity in travel: the Experiences marketplace, anchored by its Viator brand. The presentation detailed the pending $700 million all-cash sale of TheFork, TripAdvisor's European restaurant reservation platform, to American Express — a transaction expected to close by year-end 2026 with net proceeds of approximately $680 million.

The divestiture is designed to sharpen TripAdvisor's focus on its two remaining brands — Viator and the flagship TripAdvisor platform — while providing capital for share repurchases, debt reduction, or acquisitions. Experiences now represent 59% of total continuing operations revenue, up from 45% three years ago, reflecting a deliberate transformation. However, investors appeared unwilling to look past the immediate deterioration in the legacy business, sending shares to levels near the bottom of the 52-week range of $9.01 to $20.16.

Market Context and Trading Activity

The severity of the decline was amplified by elevated trading volume that far exceeded the daily average, as institutional and retail investors rushed to reprice the stock in the wake of the earnings shock. Shares gapped down at the open to approximately $10.94 — well below the prior close of $13.99 — and continued to face selling pressure throughout the session.

The move was company-specific rather than sector-driven. While broader travel and consumer discretionary names have faced macroeconomic headwinds in recent months, TripAdvisor's 26% intraday decline far outpaced any weakness in travel-sector ETFs or peers. The stock had previously rallied approximately 34% over the prior three months, partly on optimism around the TheFork transaction and the experiences-led strategy, making the reversal all the more abrupt as that bullish thesis collided with hard quarterly numbers.

With Thursday's plunge, TRIP broke decisively below both its 50-day simple moving average of approximately $13.29 and its 200-day moving average near $11.74, triggering additional technical selling pressure as stop-losses were hit and momentum traders exited positions.

What Comes Next for TRIP

The path forward for TripAdvisor hinges on execution during a period of significant transition. The TheFork sale, once finalized, will provide a substantial cash infusion that management can deploy toward buybacks or debt paydown — total debt stood at $836 million as of June 30, 2026. However, the company must also demonstrate that its Experiences segment can deliver the consistent, profitable growth needed to offset the structural decline of its legacy Hotels business.

Analyst sentiment was already cautious heading into the report, with the stock carrying an average "Reduce" rating and 5 out of 16 covering analysts issuing Sell recommendations. Post-earnings downgrades or price-target cuts could add further pressure in the coming days. Key risks include continued softening in transatlantic travel demand, further degradation of organic search traffic, and execution risk around the integration of AI-driven initiatives with partners such as Google Gemini, OpenAI, and Perplexity. The company's next quarterly update will be closely scrutinized for evidence that management's "transitory" characterization of current headwinds is accurate.

Trending AI Robots

For traders seeking to navigate volatile market conditions with data-driven precision, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to shifting market dynamics. Tickeron maintains a marketplace of hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current conditions are featured in the Trending AI Robots section. Each bot varies by strategy, timeframe, performance metrics, and the symbols it trades, enabling users to explore systematic approaches that align with their own trading objectives.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TRIP

TRIP in downward trend: price may decline as a result of having broken its higher Bollinger Band on July 16, 2026

TRIP broke above its upper Bollinger Band on July 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 33 similar instances where the stock broke above the upper band. In of the 33 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for TRIP moved out of overbought territory on July 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where TRIP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for TRIP turned negative on July 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRIP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on TRIP as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for TRIP moved above the 200-day moving average on July 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRIP advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 153 cases where TRIP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TRIP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.610) is normal, around the industry mean (29.261). P/E Ratio (127.182) is within average values for comparable stocks, (62.685). TRIP's Projected Growth (PEG Ratio) (0.318) is slightly lower than the industry average of (1.342). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.930) is also within normal values, averaging (3.121).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRIP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.

Notable companies

The most notable companies in this group are Booking Holdings Inc. (NASDAQ:BKNG), Royal Caribbean Group (NYSE:RCL), Carnival Corporation Ltd. (NYSE:CCL), Expedia Group (NASDAQ:EXPE), Trip.com Group Limited (NASDAQ:TCOM).

Industry description

Consumer sundries companies make products that usually do not have another classification, such as lawn and garden products, pest-control products, pet food and pet products like leashes, collars, and harnesses. Central Garden & Pet Company and Dogness (International) Corporation are examples of companies operating in this industry.

Market Cap

The average market capitalization across the Consumer Sundries Industry is 28.92B. The market cap for tickers in the group ranges from 4.32M to 155.55B. BKNG holds the highest valuation in this group at 155.55B. The lowest valued company is SOSAF at 4.32M.

High and low price notable news

The average weekly price growth across all stocks in the Consumer Sundries Industry was 2%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 2%. AHMA experienced the highest price growth at 23%, while PRSU experienced the biggest fall at -5%.

Volume

The average weekly volume growth across all stocks in the Consumer Sundries Industry was -19%. For the same stocks of the Industry, the average monthly volume growth was 7% and the average quarterly volume growth was -34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 64
Price Growth Rating: 48
SMR Rating: 58
Profit Risk Rating: 77
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
TRIP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of on line travel arrangement services

Industry ConsumerSundries

Profile
Details
Industry
Other Consumer Services
Address
400 1st Avenue
Phone
+1 781 800-5000
Employees
2845
Web
https://www.tripadvisor.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.